{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:28:28Z","timestamp":1778275708894,"version":"3.51.4"},"reference-count":68,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2014,11,25]],"date-time":"2014-11-25T00:00:00Z","timestamp":1416873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:p>Ibrutinib, a Bruton\u2019s kinase inhibitor, was granted an accelerated approval by the US Food and Drug Administration in November, 2013, for the treatment of relapsed or refractory mantle cell lymphoma and subsequently for the treatment of relapsed refractory chronic lymphocytic leukemia in February, 2014. In the pivotal phase 2 study of 111 patients with relapsed or refractory mantle cell lymphoma, the overall response rate in patients who received ibrutinib 560\u2009mg daily was 68%. The median progression-free survival was 13.9 months, and the overall survival was 58% at 18 months. In a recently published phase 3 trial (RESONATE) that compared ibrutinib and ofatumumab for the treatment of relapsed and refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, ibrutinib at the daily dosage of 420\u2009mg demonstrated a significantly higher overall response rate (43% in ibrutinib vs. 4% in ofatumumab) and a significantly improved overall survival at 12 months (90% ibrutinib vs. 81% ofatumumab). Similar clinical benefits were shown regardless of del (17\u2009p). Ibrutinib was well tolerated, and dose-limiting toxicity was not observed. Ibrutinib has shown durable remission, improved progression-free survival and overall survival, and favorable safety profile in indolent B-cell lymphoid malignancies. Ibrutinib, as a monotherapy, is an effective treatment modality as a salvage therapy for treatment of mantle cell lymphoma and chronic lymphocytic leukemia \/ small lymphocytic lymphoma, particularly in older patients (age \u226570 years) who are not a candidate for intensive chemotherapy and\/or those with del (17\u2009p). In patients with chronic lymphocytic leukemia and del (17\u2009p), the current practice guideline recommends ibrutinib as an upfront treatment option. Current on-going trials will further define its role as upfront therapy and\/or as a combination therapy in indolent B-cell lymphoid malignancies.<\/jats:p>","DOI":"10.1177\/1078155214561281","type":"journal-article","created":{"date-parts":[[2014,11,26]],"date-time":"2014-11-26T00:34:48Z","timestamp":1416962088000},"page":"92-104","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":58,"title":["A review of a novel, Bruton\u2019s tyrosine kinase inhibitor, ibrutinib"],"prefix":"10.1177","volume":"22","author":[{"given":"Chung-Shien","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Mount Sinai Hospital, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad A","family":"Rattu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Mount Sinai Hospital, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara S","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Mount Sinai Hospital, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2014,11,25]]},"reference":[{"key":"bibr1-1078155214561281","unstructured":"Non-Hodgkin Lymphoma. National Cancer Institute. http:\/\/www.cancer.gov\/cancertopics\/types\/non-hodgkin (accessed 3 May 2014)."},{"key":"bibr2-1078155214561281","doi-asserted-by":"publisher","DOI":"10.1186\/2162-3619-3-4"},{"key":"bibr3-1078155214561281","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.65.3.286"},{"key":"bibr4-1078155214561281","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107"},{"key":"bibr5-1078155214561281","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.07.028"},{"key":"bibr6-1078155214561281","unstructured":"Product Information: Imbruvica (ibrutinib) oral capsules. Sunnyvale, CA: Pharmacyclics Inc, Feb 2014."},{"key":"bibr7-1078155214561281","unstructured":"FDA approves Imbruvica to treat chronic lymphocytic leukemia. US Food and Drug Administration, http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm374761.htm (accessed 3 May 2014)."},{"key":"bibr8-1078155214561281","unstructured":"FDA approves Imbruvica to treat chronic lymphocytic leukemia. US Food and Drug Administration. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm385764.htm (accessed 3 May 2014)."},{"key":"bibr9-1078155214561281","unstructured":"US Food and Drug Administration Approves IMBRUVICA\u2122 (ibrutinib) as a single agent for patients with chronic lymphocytic leukemia who have received at least one prior therapy. Pharmacyclics, http:\/\/www.imbruvica.com\/downloads\/Pharmacyclics_Press_Release.pdf. (accessed 3 May 2014)."},{"key":"bibr10-1078155214561281","unstructured":"IMBRUVICA\u2122 (ibrutinib) Now Approved in the US for Patients with chronic lymphocytic leukemia who have received at least one prior therapy. Janssen, http:\/\/www.imbruvica.com\/downloads\/Janssen_Press_Release.pdf (accessed 3 May 2014)."},{"key":"bibr11-1078155214561281","unstructured":"Fact Sheet: Breathrough Therapies. US Food and Drug Administration, http:\/\/www.fda.gov\/RegulatoryInformation\/Legislation\/FederalFoodDrugandCosmeticActFDCAct\/SignificantAmendmentstotheFDCAct\/FDASIA\/ucm329491.htm (accessed 11 September 2014)."},{"key":"bibr12-1078155214561281","unstructured":"CDER Breakthrough Therapy Products Approved in Calendar Year (CY) 2013. US Food and Drug Administration, http:\/\/www.fda.gov\/downloads\/RegulatoryInformation\/Legislation\/FederalFoodDrugandCosmeticActFDCAct\/SignificantAmendmentstotheFDCAct\/FDASIA\/UCM376885.pdf (accessed 11 September 2014)."},{"key":"bibr13-1078155214561281","unstructured":"CY 2014 CDER Breakthrough Therapy Calendar Year Approvals. US Food and Drug Administration, http:\/\/www.fda.gov\/downloads\/RegulatoryInformation\/Legislation\/FederalFoodDrugandCosmeticActFDCAct\/SignificantAmendmentstotheFDCAct\/FDASIA\/UCM380724.pdf (accessed 11 September 2014)."},{"key":"bibr14-1078155214561281","unstructured":"Stephens DM and Byrd JC. Chronic lymphocytic leukemia with del(17p13.1): a distinct clinical subtype requiring novel treatment approaches.\n                      Oncology\n                      (Williston Park) 2012; 26: 1044\u20131054."},{"key":"bibr15-1078155214561281","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.502"},{"key":"bibr16-1078155214561281","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"bibr17-1078155214561281","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"bibr18-1078155214561281","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"bibr19-1078155214561281","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70513-8"},{"key":"bibr20-1078155214561281","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"bibr21-1078155214561281","doi-asserted-by":"crossref","unstructured":"Burger J, Wierda W, Hoellenriegel J, et\u00a0al\n                      .\n                      The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia (CLL) patients (abstract 187).\n                      Blood\n                      2012;120.","DOI":"10.1182\/blood.V120.21.187.187"},{"key":"bibr22-1078155214561281","unstructured":"Brown J. Combination of the Bruton\u2019s tyrosine kinase inhibitor PCI-32765 with bendamustine\/rituximab (BR) in patients with relapsed\/refractory chronic lymphocytic leukemia: interim results of a phase Ib\/II study (abstract 1590). EHA Meet 2012."},{"key":"bibr23-1078155214561281","doi-asserted-by":"crossref","unstructured":"Jaglowski SM, Jones JA, Flynn JM, et\u00a0al. A phase Ib\/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and related diseases (abstract 6508).\n                      J Clin Oncol\n                      2012.","DOI":"10.1200\/jco.2012.30.15_suppl.6508"},{"key":"bibr24-1078155214561281","doi-asserted-by":"crossref","unstructured":"Younes A, Flinn I, Berdeja JG, et\u00a0al. Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL) (abstract 8502).\n                      J Clin Oncol\n                      2013; 31 (suppl).","DOI":"10.1200\/jco.2013.31.15_suppl.8502"},{"key":"bibr25-1078155214561281","unstructured":"Akinleye A, Furqan M and Adekunle O. Ibrutinib and indolent B-cell lymphomas.\n                      Clin Lymphoma Myeloma Leuk\n                      2013; S2152\u20132650: 00470\u201300479."},{"key":"bibr26-1078155214561281","doi-asserted-by":"crossref","unstructured":"Fowler N, Advani RH, Sharman J, et\u00a0al. The Bruton\u2019s tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma (abstract 156).\n                      Blood\n                      2012; 120.","DOI":"10.1182\/blood.V120.21.156.156"},{"key":"bibr27-1078155214561281","doi-asserted-by":"crossref","unstructured":"Blum K, Christian B, Flynn JM, et\u00a0al\n                      .\n                      A Phase I trial of the Bruton\u2019s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), in combination with rituximab (R) and bendamustine in patients with relapsed\/refractory non-Hodgkin\u2019s lymphoma (NHL) (abstract 1643).\n                      Blood\n                      2012; 120.","DOI":"10.1182\/blood.V120.21.1643.1643"},{"key":"bibr28-1078155214561281","doi-asserted-by":"crossref","unstructured":"Wilson WH, Gerecitano JF, Goy A, et\u00a0al. The Bruton\u2019s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed\/refractory de novo diffuse large B-cell lymphoma (DLBCL); interim results of a multicenter, open-label, phase 2 study (abstract 686).\n                      Blood\n                      2012; 120.","DOI":"10.1182\/blood.V120.21.686.686"},{"key":"bibr29-1078155214561281","unstructured":"Pharmacyclics. A multicenter, open-label, phase 3 study of the Bruton\u2019s tyrosine kinase inhibitor PCI-32765 versus chlorambucil in patients 65 years or older with treatment-na\u00efve chronic lymphocytic leukemia or small lymphocytic lymphoma (RESONATE\u2122-2), http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01722487?term=NCT01722487&rank=1 (accessed 10 May 2014)."},{"key":"bibr30-1078155214561281","unstructured":"Pharmacyclics. A multicenter phase 2 study of PCI-32765 (ibrutinib) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with 17p deletion, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01744691?term=NCT01744691&rank=1 (accessed 10 May 2014)."},{"key":"bibr31-1078155214561281","unstructured":"Janssen Research & Development, LLC. A study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01611090?term=NCT01611090&rank=1 (accessed 10 May 2014)."},{"key":"bibr32-1078155214561281","unstructured":"MD Anderson Cancer Center. Ibrutinib versus ibrutinib + rituximab in patients with relapsed chronic lymphocytic leukemia, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02007044?term=NCT02007044&rank=1 (accessed 10 May 2014)."},{"key":"bibr33-1078155214561281","unstructured":"Kami Maddocks. PCI-32765 (ibrutinib) in treating patients with relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, or B-cell prolymphocytic leukemia, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01589302?term=NCT01589302&rank=1 (accessed 10 May 2014)."},{"key":"bibr34-1078155214561281","unstructured":"National Cancer Institute. Rituximab and bendamustine hydrochloride, rituximab and ibrutinib, or ibrutinib alone in treating older patients with previously untreated chronic lymphocytic leukemia, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01886872?term=NCT01886872&rank=1 (accessed 10 May 2014)."},{"key":"bibr35-1078155214561281","unstructured":"National Cancer Institute. Lenalidomide and ibrutinib in treating patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01886859?term=NCT01886859&rank=1 (accessed 10 May 2014)."},{"key":"bibr36-1078155214561281","unstructured":"TG Therapeutics. Ublituximab + ibrutinib in select B-cell malignancies, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02013128?term=NCT02013128&rank=1 (accessed 10 May 2014)."},{"key":"bibr37-1078155214561281","unstructured":"National Cancer Institute. Ibrutinib and rituximab compared with fludarabine phosphate, cyclophosphamide, and rituximab in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02048813?term=NCT02048813&rank=1 (accessed 10 May 2014)."},{"key":"bibr38-1078155214561281","unstructured":"Janssen Research & Development, LLC. A study of PCI-32765 (ibrutinnib) versus rituximab in relapsed or refractory chronic leukemia\/lymphoma, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01973387?term=NCT01973387&rank=1 (accessed 10 May 2014)."},{"key":"bibr39-1078155214561281","unstructured":"National Cancer Institute. Ibrutinib in treating patients with relapsed or refractory follicular lymphoma, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01849263?term=NCT01849263&rank=1 (accessed 10 May 2014)."},{"key":"bibr40-1078155214561281","unstructured":"National Heart, Lung, and Blood Institute. PCI-32765 for special cases of chronic lymphocytic leukemia or small lymphocytic lymphoma, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01500733?term=NCT01500733&rank=1 (accessed 10 May 2014)."},{"key":"bibr41-1078155214561281","unstructured":"MD Anderson Cancer Center. Phase 2 study of the combination of Bruton\u2019s tyrosine kinase inhibitor PCI-32765 and rituximab in high-risk chronic lymphocytic leukemia and small lymphocytic lymphoma patients, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01520519?term=NCT01520519&rank=1 (accessed 10 May 2014)."},{"key":"bibr42-1078155214561281","unstructured":"Janssen Research & Development, LLC. Study of ibrutinib (a Bruton\u2019s tyrosine kinase inhibitor), versus temsirolimus in patients with relapsed or refractory mantle cell lymphoma who have received at least one prior therapy, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01646021?term=NCT01646021&rank=1 (accessed 10 May 2014)."},{"key":"bibr43-1078155214561281","unstructured":"Janssen Research & Development, LLC. A study of the Bruton\u2019s tyrosine kinase inhibitor ibrutinib given in combination with bendamustine and rituximab in patients with newly diagnosed mantle cell lymphoma, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01776840?term=NCT01776840&rank=1 (accessed 10 May 2014)."},{"key":"bibr44-1078155214561281","unstructured":"Janssen Research & Development, LLC. A study to evaluate the efficacy and safety of ibrutinib, in patients with mantle cell lymphoma who progress after bortezomib therapy, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01599949?term=NCT01599949&rank=1 (accessed 10 May 2014)."},{"key":"bibr45-1078155214561281","unstructured":"MD Anderson Cancer Center. Phase 2 ibrutinib + rituximab in relapsed\/refractory mantle cell lymphoma, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01880567?term=NCT01880567&rank=1 (accessed 10 May 2014)."},{"key":"bibr46-1078155214561281","unstructured":"Janssen Research & Development, LLC. A study of PCI-32765 (ibrutinib) in patients with refractory follicular lymphoma, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01779791?term=NCT01779791&rank=1 (accessed 10 May 2014)."},{"key":"bibr47-1078155214561281","unstructured":"Pharmacyclics. Study of the Bruton\u2019s tyrosine kinase inhibitor in combination with rituximab in previously untreated subjects with follicular lymphoma http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01980654?term=NCT01980654&rank=1 (accessed 10 May 2014)."},{"key":"bibr48-1078155214561281","unstructured":"National Cancer Institute. Rituximab, lenalidomide, and ibrutinnib in treating patients with previously untreated stage II-IV follicular lymphoma, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01829568?term=NCT01829568&rank=1 (accessed 10 May 2014)."},{"key":"bibr49-1078155214561281","unstructured":"Janssen Research & Development, LLC. A study of PCI-32765 (ibrutinib) in combination with either bendamustine and rituximab or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously treated indolent non-Hodgkin lymphoma, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01974440?term=NCT01974440&rank=1 (accessed 10 May 2014)."},{"key":"bibr50-1078155214561281","unstructured":"Pharmacyclics. Study of the Bruton\u2019s tyrosine kinase inhibitor in subjects with relapsed\/refractory marginal zone lymphoma, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01980628?term=NCT01980628&rank=1 (accessed 10 May 2014)."},{"key":"bibr51-1078155214561281","unstructured":"Janssen Research & Development, LLC. A study of the Bruton\u2019s tyrosine kinase inhibitor, PCI-32765 (ibrutinib), in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with newly diagnosed non-germinal center B-cell subtype of diffuse large B-cell lymphoma, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01855750?term=NCT01855750&rank=1 (accessed 10 May 2014)."},{"key":"bibr52-1078155214561281","unstructured":"National Cancer Institute. Lenalidomide and ibrutinib in treating patients with relapsed or refractory B-cell non-Hodgkin lymphoma, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01955499?term=NCT01955499&rank=1 (accessed 10 May 2014)."},{"key":"bibr53-1078155214561281","unstructured":"The Lymphoma Academic Research Organization. Bruton\u2019s tyrosine kinase inhibition in B-cell lymphomas (BIBLOS), http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02055924?term=NCT02055924&rank=1 (accessed 10 May 2014)."},{"key":"bibr54-1078155214561281","unstructured":"Pharmacyclics. Ibrutinib in combination with lenalidomide, with and without rituximab in participants with relapsed or refractory diffuse large B-cell lymphoma, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02077166?term=NCT02077166&rank=1 (accessed 10 May 2014)."},{"key":"bibr55-1078155214561281","unstructured":"Kristie Blum. Rituxan\/bendamustine\/PCI-32765 in relapsed DLBCL, MCL, or indolent non-Hodgkin\u2019s lymphoma, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01479842?term=NCT01479842&rank=1 (accessed 10 May 2014)."},{"key":"bibr56-1078155214561281","unstructured":"Janssen Pharmaceutical K.K. A study to evaluate the Bruton\u2019s tyrosine kinase inhibitor PCI-32765 in patients with recurrent mature B-cell neoplasms, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01704963?term=NCT01704963&rank=1 (accessed 10 May 2014)."},{"key":"bibr57-1078155214561281","unstructured":"National Cancer Institute. Ibrutinib in treating patients with relapsed hairy cell leukemia, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01841723?term=NCT01981512&rank=1 (accessed 10 May 2014)."},{"key":"bibr58-1078155214561281","unstructured":"Dana-Farber Cancer Institute. Ibrutinib (PCI-32765) in Waldenstrom\u2019s Macroglobulinemia, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01614821?term=NCT01614821&rank=1 (accessed 10 May 2014)."},{"key":"bibr59-1078155214561281","unstructured":"Pharmacyclics. Study of the Bruton\u2019s tyrosine kinase inhibitor in combination with carfilzomib (Kyprolis\u2122), in subjects with relapsed or relapsed and refractory multiple myeloma, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01962792?term=NCT01962792&rank=1 (accessed 10 May 2014)."},{"key":"bibr60-1078155214561281","unstructured":"Pharmacyclics. Study of the Bruton\u2019s tyrosine kinase inhibitor in subjects with relapsed or relapsed and refractory multiple myeloma, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01478581?term=NCT01478581&rank=1 (accessed 10 May 2014)."},{"key":"bibr61-1078155214561281","doi-asserted-by":"crossref","unstructured":"Neffendorf JE, Gout I and Hildebrand GD. Ibrutinib in relapsed chronic lymphocytic leukemia.\n                      N Engl J Med\n                      2013; 369: 1277.","DOI":"10.1056\/NEJMc1309710"},{"key":"bibr62-1078155214561281","unstructured":"A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Participants. US National Institutes of Health, http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01626651 (accessed 3 May 2014)."},{"key":"bibr63-1078155214561281","doi-asserted-by":"crossref","unstructured":"Farooqui M, Lozier JN, Valdez J, et\u00a0al. Ibrutinib (PCI-32765) rapidly improves platelet counts in chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) patients and has minimal effects on platelet aggregation (abstract 1789).\n                      Blood\n                      2012; 120.","DOI":"10.1182\/blood.V120.21.1789.1789"},{"key":"bibr64-1078155214561281","unstructured":"RedBook [online database], http:\/\/www.redbook.com\/redbook\/online (accessed 3 May 2014)."},{"key":"bibr65-1078155214561281","unstructured":"IMBRUVICA\u2122 | YOU&i Access Program. Pharmacyclics, http:\/\/www.imbruvica.com\/access (accessed 3 May 2014)."},{"key":"bibr66-1078155214561281","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-396853"},{"key":"bibr67-1078155214561281","unstructured":"Application Number 205552Orig1s000. Center for Drug Evaluation and Research, http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/205552Orig1s000ChemR.pdf. (accessed 3 May 2014)."},{"key":"bibr68-1078155214561281","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non-Hodgkin\u2019s Lymphomas V.2.2014. www.nccn.org. (accessed 10 May 2014)."}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155214561281","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155214561281","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155214561281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:16:00Z","timestamp":1777688160000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155214561281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,25]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1177\/1078155214561281"],"URL":"https:\/\/doi.org\/10.1177\/1078155214561281","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,25]]}}}